Galicaftor - AbbVie/Galapagos NV
Alternative Names: ABBV 2222; GLPG-2222; SION-2222Latest Information Update: 16 Jun 2025
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer AbbVie; Galapagos NV
- Class Amides; Antifibrotics; Benzoic acids; Chromans; Cyclopropanes; Dioxolanes; Fluorinated hydrocarbons; Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis
Most Recent Events
- 06 Jun 2025 Pharmacodynamics data from a preclinical study in Cystic fibrosis released in Sionna Therapeutics
- 20 Mar 2025 Sionna Therapeutics plans a phase I MAD trial for Cystic fibrosis (In volunteers, Combination therapy) in the second half of 2025
- 16 Jul 2024 Sionna Therapeutics in-licenses Galicaftor from AbbVie